Thirdly, although many previous NMAs analyzed some preferable choices for EGFR-mutated advanced NSCLC based on different mutation status [14], some important data were not available at that time (these include final OS for FLAURA and NEJ026 study, PFS for CTONG-1509, RELAY, and ACTIVE study) [7, 8, 15–18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.